Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA®
06 September 2023 - 11:58PM
Business Wire
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye
health company dedicated to helping people see better to live
better, today announced that it has disclosed certain historical
and pro forma financial information with respect to its proposed
acquisition of XIIDRA (lifitegrast ophthalmic solution) 5% and
certain other ophthalmology assets (“Acquisition”) on a Current
Report on Form 8-K and on its SEDAR+ (www.sedarplus.ca) profile. In
connection with the Acquisition, as previously disclosed, Bausch +
Lomb anticipates incurring indebtedness (expected to be comprised
principally of an incremental term loan and the issuance of senior
secured notes), which is discussed in further detail in its Current
Report on Form 8-K.
About Bausch + Lomb Bausch + Lomb is dedicated to
protecting and enhancing the gift of sight for millions of people
around the world – from the moment of birth through every phase of
life. Its comprehensive portfolio of more than 400 products
includes contact lenses, lens care products, eye care products,
ophthalmic pharmaceuticals, over-the-counter products and
ophthalmic surgical devices and instruments. Founded in 1853,
Bausch + Lomb has a significant global research and development,
manufacturing and commercial footprint with approximately 13,000
employees and a presence in nearly 100 countries. Bausch + Lomb is
headquartered in Vaughan, Ontario with corporate offices in
Bridgewater, New Jersey. For more information, visit www.bausch.com
and connect with us on Twitter, LinkedIn, Facebook and
Instagram.
Forward-looking Statements This news release may contain
forward-looking statements, including statements related to the
proposed Acquisition and the anticipated indebtedness to be
incurred in connection with the Acquisition, which may generally be
identified by the use of the words “anticipates,” “hopes,”
“expects,” “intends,” “plans,” “should,” “could,” “would,” “will,”
“may,” “believes,” “estimates,” “potential,” “target,” or
“continue” and variations or similar expressions. These statements
are based upon the current expectations and beliefs of management
and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include,
but are not limited to, the risks and uncertainties discussed in
Bausch + Lomb’s filings with the U.S. Securities and Exchange
Commission and the Canadian Securities Administrators, which
factors are incorporated herein by reference. They also include
risks and uncertainties respecting the XIIDRA acquisition,
including uncertainties relating to the timing of the consummation
of that transaction; the possibility that any or all of the
conditions to the consummation of that transaction may not be
satisfied or waived; the effect of the announcement or pendency of
that transaction on Bausch + Lomb’s ability to maintain
relationships with customers, suppliers and other business
partners; the impact of the transaction if consummated on Bausch +
Lomb’s business, financial position and results of operations;
risks relating to potential diversion of management attention away
from Bausch + Lomb’s ongoing business operations; Bausch + Lomb’s
ability to finance the transaction as anticipated, the terms of
such financing and risks relating to increased levels of debt as a
result of debt expected to be incurred to finance such transaction;
and risks that Bausch + Lomb may not realize the expected benefits
of that transaction on a timely basis or at all. Readers are
cautioned not to place undue reliance on any of these
forward-looking statements. These forward-looking statements speak
only as of the date hereof. Bausch + Lomb undertakes no obligation
to update any of these forward-looking statements to reflect events
or circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
© 2023 Bausch + Lomb.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230905589419/en/
Media Contacts: T.J. Crawford tj.crawford@bausch.com
(908) 705-2851
Lainie Keller lainie.keller@bausch.com (908) 927-1198
Investor Contact: George Gadkowski
george.gadkowski@bausch.com (877) 354-3705 (toll free) (908)
927-0735
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
Von Mai 2023 bis Mai 2024